查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954435

日本非专利注射剂市场：规模、份额、趋势和预测：按治疗领域、包装容器、销售管道和地区划分，2026-2034年

Japan Generic Injectables Market Size, Share, Trends and Forecast by Therapeutic Area, Container, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本非专利达19亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到71亿美元，2026年至2034年的复合年增长率（CAGR）为16.05%。推动这一市场成长的因素包括：高价值注射剂专利到期、国民健康保险（NHI）报销政策的有利续期、国内注射剂产品组合的扩大、以成本为导向的采购改革、临床接受度的提高、日本药品和医疗设备管理局（PMDA）监管信誉的提升、电子处方笺的推广、药物监测工作的加强，以及肿瘤科、肾内科和急诊科的强化科。

日本非专利注射药品市场趋势：

高价值注射剂类药物专利到期

日本製药业正面临专利到期潮，尤其是用于癌症治疗、自体免疫疾病和代谢紊乱的高价值注射剂。在专利悬崖的背景下，非专利生产商正抓住注射剂领域的机会，因为注射剂的价格利润率仍然高于口服非专利。国民健康保险（NHI）体係正透过更新报销标准和积极采用更具成本效益的替代疗法来支持这项转型。这种法规环境直接影响日本注射非专利药的市场份额，尤其是在高成本的住院治疗领域，使学名药能够更便捷地进入处方药目录并获得临床应用。大型医院和地区医疗中心正在调整采购惯例以适应修订后的定价模式，从而建立起优先采购可靠且价格具有竞争力的学名药的采购流程。根据最新的2024年调查，自2021年以来，日本的监管改革促使整个行业对无菌生产技术的投资大幅增加，超过40%的受访企业表示已主动升级设备以符合修订后的GMP标准。日工製药和泽井製药等日本国内企业正抓住这些机会，拓展注射剂产品线并提升产能。随着原厂药价格持续下调，学名药在疗效方面与原厂药趋于一致，非专利注射剂的市场环境日益改善。尤其值得一提的是，2025年2月21日，中央药品价格委员会正式核准了2025年药品价格调整方案，该方案将于4月生效。此次调整包括强化专利到期药的降价机制、重新评估定价标准以及提供更多奖励以确保稳定供应，所有这些都将直接影响学名药的定价和报销。预计这些变化将透过加大价格压力和支持重点製剂的持续供应，重塑日本学名药市场的市场动态。此外，由于医疗机构采购部门日益重视供应保障和上市后监管，日本生产商也正将这些要素融入生产和物流流程，市场前景依然乐观。

医疗机构的信任度和品质保证有助于提高医生和病人的接受度。

在日本，保守的处方习惯历来阻碍了非专利，尤其是注射剂的普及。根据最新的2024年报告，注射剂仅占日本学名药总量的6.8%，却占市场份额的26.4%，凸显了其高成本的成本。此外，80%的注射非专利药由仅10家公司生产，而仅有9.4%的生产设施完全符合最新标准的GMP规范。然而，随着日本药品和医疗设备管理局（PMDA）严格的监管，人们对该体系的信心正在增强。日本国内生产商正致力于确保产品品质的稳定性、透明的生产审核以及完善的药品监测体系，这增强了医疗服务提供者的信心。这种行为转变正促使肿瘤科、肾臟科和急诊科等对非专利药依赖性高的领域更多地采用注射剂仿製药，这些领域对临床疗效和供应可靠性要求极高，从而推动了日本注射剂非专利药市场的整体增长。处方医生会收到关于经济实惠的替代药物的电子通知，病患教育计画也在强化已通过核准的非专利的等效性。这些变化在需要长期注射治疗的领域尤其重要，因为这些领域的成本节约可以迅速累积。药品分发奖励和药品目录层面的调整正在规范当地医疗机构中学名药的使用。在政策支持、医院稳定需求以及临床偏好模式的显着转变（尤其是对具有可靠临床记录和严格生产标准的学名药的偏好）的推动下，日本非专利注射剂市场的长期前景正朝着有利的方向发展。

本报告解答的主要问题

  • 日本非专利注射剂市场至今发展状况如何？未来几年预计又将如何发展？
  • 日本非专利注射剂市场按治疗领域分類的情况如何？
  • 日本非专利注射剂市场按包装类型分類的细分情况如何？
  • 日本非专利注射剂市场依销售管道分類的情况如何？
  • 日本非专利注射剂市场按地区分類的情况如何？
  • 日本非专利注射剂市场价值链的不同阶段有哪些？
  • 日本非专利注射剂市场的主要驱动因素和挑战是什么？
  • 日本非专利注射剂市场的结构是怎么样的？主要企业有哪些？
  • 日本非专利注射剂市场竞争程度如何？

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
  • 市场估值
  • 调查方法

第三章执行摘要

第四章：日本非专利仿製药市场：简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争资讯

第五章：日本非专利仿製药市场：现状

  • 过去与现在的市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章：日本非专利仿製药市场：依治疗领域划分

  • 肿瘤学
  • 麻醉
  • 抗感染药物
  • 静脉营养
  • 循环系统

第七章：日本非专利仿製药市场：依容器类型划分

  • 管瓶
  • 安瓿
  • 预混合料
  • 预填充式注射器

第八章：日本非专利仿製药市场：依销售管道细分

  • 医院
  • 零售药房

第九章：日本非专利仿製药市场：区域分析

  • 关东地区
  • 关西、近畿地区
  • 中部地区
  • 九州和冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十章：日本非专利仿製药市场：竞争格局

  • 概述
  • 市场结构
  • 市场定位
  • 关键成功策略
  • 竞争对手仪錶板
  • 企业估值象限

第十一章：主要企业概况

第十二章：日本非专利仿製药市场：产业分析

  • 促进因素、抑制因素和机会
  • 波特五力分析
  • 价值链分析

第十三章附录

简介目录
Product Code: SR112026A33026

The Japan generic injectables market size reached USD 1.9 Billion in 2025 . Looking forward, IMARC Group expects the market to reach USD 7.1 Billion by 2034 , exhibiting a growth rate (CAGR) of 16.05 % during 2026-2034 . Patent expirations in high-value injectables, favorable NHI reimbursement updates, expanded domestic parenteral portfolios, cost-driven procurement reforms, improved clinical acceptance, PMDA-backed regulatory confidence, electronic prescribing prompts, pharmacovigilance efforts, and increased hospital adoption across oncology, nephrology, and emergency care are some of the factors positively impacting the market.

JAPAN GENERIC INJECTABLES MARKET TRENDS:

Patent Expirations Across High-Value Injectable Drug Classes

Japan's pharmaceutical sector has entered a cycle of frequent patent expirations, particularly across high-value injectable drugs used in oncology, autoimmune diseases, and metabolic disorders. As these patent cliffs occur, generic manufacturers are seizing the opportunity to enter the injectable space, where price margins remain more favorable than oral generics. The National Health Insurance (NHI) system supports this shift by updating reimbursement rates and actively favoring cost-effective alternatives. This regulatory environment has directly influenced the Japan generic injectables market share, particularly in high-cost hospital-based therapies, giving generics significant access to formulary placement and clinical adoption. Major hospitals and regional centers are adjusting procurement practices to align with revised pricing models, resulting in procurement cycles that favor reliable and price-competitive generics. As per a recent 2024 study, regulatory reforms in Japan post-2021 have led to a notable increase in industry-wide investment in sterile manufacturing technologies, with over 40% of surveyed companies reporting active upgrades to meet revised GMP standards. Domestic companies, such as Nichi-Iko and Sawai, are leveraging these opportunities with expanded parenteral portfolios and increased capacity. With originator prices consistently revised downward and generics gaining parity in therapeutic trust, the landscape for injectable generics is strengthening. Notably, on February 21, 2025, Chuikyo formally approved the pricing rules for Japan's FY2025 drug price revision, which will come into effect in April. The revision includes tighter price reduction mechanisms for off-patent drugs, revised repricing criteria, and further incentives for stable supply, all of which directly influence generic injectable pricing and reimbursement. These changes are expected to reshape market dynamics for injectable generics in Japan by reinforcing pricing pressure while supporting supply continuity for high-priority formulations. Institutional buyers are further placing increasing emphasis on supply assurance and post-marketing monitoring, which Japanese manufacturers have integrated into their production and logistics workflows, thereby creating a positive market outlook.

Physician and Patient Acceptance Driven by Institutional Trust and Quality Assurance

In Japan, conservative prescribing patterns have historically slowed generic uptake, particularly in injectables. As per a recent 2024 report, injectables accounted for only 6.8% of Japan's generic drug volume but made up 26.4% of its market value, underscoring their high-cost concentration. Additionally, 80% of injectable generics were produced by just 10 companies, with only 9.4% of facilities meeting full GMP compliance under updated standards. However, institutional trust has grown in tandem with stringent regulatory oversight by the Pharmaceuticals and Medical Devices Agency (PMDA). Domestic manufacturers have focused on quality consistency, transparent manufacturing audits, and strong pharmacovigilance programs, which have reassured healthcare providers. This behavioral shift is contributing to the overall Japan generic injectables market growth, as it has led to broader adoption of generic injectables in high-dependency areas such as oncology, nephrology, and emergency care, where clinical outcomes and supply reliability are critical. Prescribers now receive electronic prompts for cost-effective alternatives, and patient education programs are reinforcing the equivalency of approved generics. These changes are particularly relevant in therapeutic classes requiring long-term injectable therapy cycles, where cost savings accumulate quickly. Dispensing incentives and formulary-level changes have started to normalize generic use even in community-level care settings. The long-term Japan generic injectables market outlook reflects a favorable shift, driven by supportive policy, steady demand from hospitals, and a measurable change in clinical preference patterns, especially for injectable generics with reliable clinical histories and robust manufacturing standards.

JAPAN GENERIC INJECTABLES MARKET SEGMENTATION:

Therapeutic Area Insights:

  • Oncology
  • Anesthesia
  • Anti-infectives
  • Parenteral Nutrition
  • Cardiovascular

Container Insights:

  • Vials
  • Ampoules
  • Premix
  • Prefilled Syringes

Distribution Channel Insights:

  • Hospitals
  • Retail Pharmacy

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan generic injectables market performed so far and how will it perform in the coming years?
  • What is the breakup of the Japan generic injectables market on the basis of therapeutic area?
  • What is the breakup of the Japan generic injectables market on the basis of container?
  • What is the breakup of the Japan generic injectables market on the basis of distribution channel?
  • What is the breakup of the Japan generic injectables market on the basis of region?
  • What are the various stages in the value chain of the Japan generic injectables market?
  • What are the key driving factors and challenges in the Japan generic injectables market?
  • What is the structure of the Japan generic injectables market and who are the key players?
  • What is the degree of competition in the Japan generic injectables market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Generic Injectables Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Generic Injectables Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Generic Injectables Market - Breakup by Therapeutic Area

  • 6.1 Oncology
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Anesthesia
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Anti-infectives
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Parenteral Nutrition
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.4.3 Market Forecast (2026-2034)
  • 6.5 Cardiovascular
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2020-2025)
    • 6.5.3 Market Forecast (2026-2034)

7 Japan Generic Injectables Market - Breakup by Container

  • 7.1 Vials
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Ampoules
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Premix
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)
  • 7.4 Prefilled Syringes
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2020-2025)
    • 7.4.3 Market Forecast (2026-2034)

8 Japan Generic Injectables Market - Breakup by Distribution Channel

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)

9 Japan Generic Injectables Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Therapeutic Area
    • 9.1.4 Market Breakup by Container
    • 9.1.5 Market Breakup by Distribution Channel
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Therapeutic Area
    • 9.2.4 Market Breakup by Container
    • 9.2.5 Market Breakup by Distribution Channel
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Therapeutic Area
    • 9.3.4 Market Breakup by Container
    • 9.3.5 Market Breakup by Distribution Channel
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Therapeutic Area
    • 9.4.4 Market Breakup by Container
    • 9.4.5 Market Breakup by Distribution Channel
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Therapeutic Area
    • 9.5.4 Market Breakup by Container
    • 9.5.5 Market Breakup by Distribution Channel
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Therapeutic Area
    • 9.6.4 Market Breakup by Container
    • 9.6.5 Market Breakup by Distribution Channel
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Therapeutic Area
    • 9.7.4 Market Breakup by Container
    • 9.7.5 Market Breakup by Distribution Channel
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Therapeutic Area
    • 9.8.4 Market Breakup by Container
    • 9.8.5 Market Breakup by Distribution Channel
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Generic Injectables Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Products Offered
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Products Offered
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Products Offered
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Products Offered
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Products Offered
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Generic Injectables Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix